[{"address1": "3160 Porter Drive", "address2": "Suite 250", "city": "Palo Alto", "state": "CA", "zip": "94304", "country": "United States", "phone": "650 391 9740", "website": "https://bridgebio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.", "fullTimeEmployees": 550, "companyOfficers": [{"maxAge": 1, "name": "Dr. Neil  Kumar Ph.D.", "age": 45, "title": "Co-Founder, CEO & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 1534840, "exercisedValue": 0, "unexercisedValue": 51135260}, {"maxAge": 1, "name": "Dr. Charles J. Homcy M.D.", "age": 76, "title": "Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director", "yearBorn": 1948, "fiscalYear": 2023, "totalPay": 563200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Frank P. McCormick Ph.D.", "age": 74, "title": "Co-Founder, Chairman of Oncology & Director", "yearBorn": 1950, "fiscalYear": 2023, "totalPay": 542778, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Brian C. Stephenson C.F.A., Ph.D.", "age": 43, "title": "CFO & Secretary", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 1151240, "exercisedValue": 0, "unexercisedValue": 16193392}, {"maxAge": 1, "name": "Dr. Richard H. Scheller Ph.D.", "age": 71, "title": "Chairman of Research & Development", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 509622, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thomas  Trimarchi Ph.D.", "title": "President & COO", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Uma  Sinha Ph.D.", "age": 66, "title": "Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 1313457, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Grace  Rauh", "title": "Vice President of Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eli M. Wallace Ph.D.", "age": 57, "title": "Chief Scientific Officer of Oncology", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric Michael David J.D., M.D., Ph.D.", "age": 52, "title": "Chief Executive Officer of Gene Therapy", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 9, "compensationRisk": 7, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 27.44, "open": 27.79, "dayLow": 27.53, "dayHigh": 28.88, "regularMarketPreviousClose": 27.44, "regularMarketOpen": 27.79, "regularMarketDayLow": 27.53, "regularMarketDayHigh": 28.88, "beta": 1.086, "forwardPE": -7.7260275, "volume": 1396041, "regularMarketVolume": 1396041, "averageVolume": 1973001, "averageVolume10days": 1759340, "averageDailyVolume10Day": 1759340, "bid": 28.09, "ask": 28.25, "bidSize": 400, "askSize": 300, "marketCap": 5329518080, "fiftyTwoWeekLow": 21.62, "fiftyTwoWeekHigh": 41.04, "priceToSalesTrailing12Months": 24.473713, "fiftyDayAverage": 25.994, "twoHundredDayAverage": 26.60505, "currency": "USD", "enterpriseValue": 6660835328, "profitMargins": -2.01529, "floatShares": 128174774, "sharesOutstanding": 188990000, "sharesShort": 17124130, "sharesShortPriorMonth": 17187425, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.09060001, "heldPercentInsiders": 0.029089998, "heldPercentInstitutions": 0.94121003, "shortRatio": 6.66, "shortPercentOfFloat": 0.1391, "impliedSharesOutstanding": 188990000, "bookValue": -6.508, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -438860000, "trailingEps": -2.42, "forwardEps": -3.06, "enterpriseToRevenue": 30.587, "enterpriseToEbitda": -13.063, "52WeekChange": -0.2567714, "SandP52WeekChange": 0.25443196, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "BBIO", "underlyingSymbol": "BBIO", "shortName": "BridgeBio Pharma, Inc.", "longName": "BridgeBio Pharma, Inc.", "firstTradeDateEpochUtc": 1561642200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d3adccf0-6693-305c-9651-8da79033d61c", "messageBoardId": "finmb_412911458", "gmtOffSetMilliseconds": -18000000, "currentPrice": 28.2, "targetHighPrice": 70.0, "targetLowPrice": 36.4, "targetMeanPrice": 48.89333, "targetMedianPrice": 48.0, "recommendationMean": 1.58824, "recommendationKey": "buy", "numberOfAnalystOpinions": 15, "totalCash": 266324000, "totalCashPerShare": 1.409, "ebitda": -509903008, "totalDebt": 1729748992, "quickRatio": 1.932, "currentRatio": 3.193, "totalRevenue": 217764992, "revenuePerShare": 1.194, "returnOnAssets": -0.48883, "freeCashflow": -365117120, "operatingCashflow": -450219008, "revenueGrowth": -0.332, "grossMargins": 0.98902, "ebitdaMargins": -2.34153, "operatingMargins": -68.49524, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-02"}]